Detalhe da pesquisa
1.
Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapy.
Eur J Haematol
; 112(1): 111-121, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526606
2.
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
Blood
; 134(7): 636-640, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31648294
3.
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Blood
; 134(19): 1585-1597, 2019 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31558469
4.
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Blood
; 133(15): 1652-1663, 2019 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30728140
5.
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Blood
; 133(17): 1876-1887, 2019 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30782611
6.
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis.
Haematologica
; 105(1): 136-147, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31018977
7.
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol
; 94(8): E209-E213, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31056762
8.
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
Blood Adv
; 8(2): 453-467, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903325
9.
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Blood Adv
; 7(11): 2449-2458, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36521030
10.
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther
; 29(7): 430-437, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031746
11.
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.
J Palliat Med
; 25(4): 614-619, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34847733
12.
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Cancer Med
; 11(22): 4104-4111, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35349227
13.
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 21(3): 176-181, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358575
14.
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
Blood Adv
; 3(20): 3062-3069, 2019 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31648329
15.
The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
Leukemia
; 33(7): 1700-1712, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30635626
16.
Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML).
J Drug Assess
; 7(1): 51-53, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30034924